Thermo Fisher Scientific Inc. has announced that it has completed its acquisition of Olink Holding AB, a provider of next-generation proteomics solutions.

AMSBIO has launched a Glucagon-Like Peptide 1 Receptor (GLP-1R) reporter cell line.

Partners to host joint conference on ‘Protein Sciences in Drug Discovery’ in Cambridge, UK from 18–19 November 2024.

AMP published a set of evidence-based recommendations for the analytical validation and reporting of tumor mutational burden (TMB) testing as a potential predictive biomarker for immune checkpoint inhibitor (ICI) therapies.

£790k FASST grant, in collaboration with DeepMirror, and £350k Engineering Biology grant awarded for platform development.

Collaboration leverages synergies of QIAGEN’s OmicSoft omics data through Evotec’s analysis platform PanHunter.

Waters Xevo™ MRT Mass Spectrometer employs next-generation multi-reflecting time-of-flight technology to deliver class-leading combination of high resolution and speed without compromising analytical performance.

At the 72nd ASMS meeting, Bruker Corporation (Nasdaq: BRKR) launches the new top-of-the-line timsTOF Ultra 2 system with significantly further enhanced sensitivity for deep profiling of small cells and subcellular organelles.

Thermo Fisher Scientific Inc. (NYSE: TMO), unveiled the Thermo Scientific™ Stellar™ mass spectrometer (MS), a new solution that combines fast throughput, high sensitivity, and ease of use.

Partnership will expand Evotec’s molecular patient database in the area of metabolic diseases and in particular obesity.